Billingsley Caroline C, Cohn David E, Mutch David G, Hade Erinn M, Goodfellow Paul J
*Division of Gynecology Oncology, Department of Obstetrics and Gynecology, The Ohio State University, College of Medicine, Columbus, OH; †Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Washington University, St Louis, MO; and ‡Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH.
Int J Gynecol Cancer. 2016 Jun;26(5):933-8. doi: 10.1097/IGC.0000000000000681.
POLE mutations in high-grade endometrioid endometrial cancer (EEC) have been associated with improved survival. We sought to investigate the prevalence of POLE tumor mutation and its prognostic significance on outcomes and clinical applications in a subanalysis of women with high-grade EEC from a previously described cohort of 544 EEC patients in which POLE mutation status and survival outcomes were assessed.
Polymerase chain reaction amplification and Sanger sequencing were used to test for POLE mutations in 72 tumors. Associations between POLE mutation, demographic and clinicopathologic features, and survival were investigated with Cox proportional hazard models.
POLE mutations were identified in 7 (9.7%) of 72 grade 3 EECs. No significant differences in the clinicopathologic features between those with POLE mutations and those without were identified. Adjusted for age, a decreased risk of recurrence was suggested in patients with a POLE mutation (adjusted hazard ratio, 0.37; 95% confidence interval, 0.09-1.55), as well as decreased risk of death (adjusted hazard ratio, 0.19; 95% confidence interval, 0.03-1.42).
POLE mutations in tumors of women with grade 3 EEC are associated with a lower risk of recurrence and death, although not statistically significant because of high variability in these estimates. These findings, consistent with recently published combined analyses, support POLE mutation status as a noteworthy prognostic marker and may favor a change in the treatment of women with grade 3 EECs, particularly in those with early-stage disease, in which omission of adjuvant therapy and decreased surveillance could possibly be appropriate.
高级别子宫内膜样腺癌(EEC)中的POLE突变与生存率提高相关。我们试图在对先前描述的544例EEC患者队列中的高级别EEC女性患者进行的亚分析中,研究POLE肿瘤突变的患病率及其对结局和临床应用的预后意义,该队列中评估了POLE突变状态和生存结局。
采用聚合酶链反应扩增和桑格测序法检测72个肿瘤中的POLE突变。使用Cox比例风险模型研究POLE突变、人口统计学和临床病理特征以及生存之间的关联。
在72例3级EEC中,有7例(9.7%)检测到POLE突变。POLE突变组和未突变组之间的临床病理特征未发现显著差异。校正年龄后,POLE突变患者的复发风险降低(校正风险比,0.37;95%置信区间,0.09 - 1.55),死亡风险也降低(校正风险比,0.19;95%置信区间,0.03 - 1.42)。
3级EEC女性患者肿瘤中的POLE突变与较低的复发和死亡风险相关,尽管由于这些估计值的高度变异性,在统计学上不显著。这些发现与最近发表的综合分析一致,支持将POLE突变状态作为一个值得关注的预后标志物,并可能有利于改变3级EEC女性患者的治疗方式,特别是对于早期疾病患者,其中省略辅助治疗和减少监测可能是合适的。